StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
AddVie (ABBV) Continues to Deliver, Despite Concerns - Analyst
October 29, 2021 9:04 AM
Earlier today, AbbVie (NYSE: ABBV) reported its Q3 results: EPS of $3.33, $0.10 better than the analyst estimate of $3.23 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Momentum Movers
Trader Talk
Next Articles
AbbVie (ABBV) Announces FDA Approval of VUITY 1.25%, the First and Only Eye Drop to Treat Presbyopia
October 29, 2021 5:33 PM
AbbVie's (ABBV) Cariprazine Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
October 29, 2021 7:51 AM
AbbVie (ABBV) Raises Quarterly Dividend 8.5% to $1.41; 5.1% Yield
October 29, 2021 7:43 AM
AbbVie (ABBV) Tops Q3 EPS by 10c, Offers Guidance
October 29, 2021 7:42 AM
AbbVie (ABBV) call put ratio 8.8 calls to 1 put into quarter results
October 28, 2021 10:44 AM
AbbVie (ABBV) Reports ABBV-951Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial
October 28, 2021 8:19 AM
